Pharmaceutical Investing Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Pharmaceutical Investing Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Blue Lagoon Continues to Strengthen Treasury to Fund Final Preparations of Mine Site and Initial Working Capital to Fund Commencement of Production
